What is William Blair’s Estimate for ADPT FY2024 Earnings?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) – Analysts at William Blair increased their FY2024 EPS estimates for shares of Adaptive Biotechnologies in a report released on Thursday, November 14th. William Blair analyst A. Brackmann now expects that the company will post earnings of ($1.09) per share for the year, up from their prior estimate of ($1.17). The consensus estimate for Adaptive Biotechnologies’ current full-year earnings is ($1.10) per share. William Blair also issued estimates for Adaptive Biotechnologies’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.94) EPS.

A number of other research firms have also issued reports on ADPT. JPMorgan Chase & Co. lifted their target price on Adaptive Biotechnologies from $5.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. BTIG Research lifted their price objective on shares of Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. Finally, Piper Sandler boosted their target price on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a report on Monday, November 11th.

Adaptive Biotechnologies Price Performance

ADPT opened at $4.48 on Monday. Adaptive Biotechnologies has a 1-year low of $2.28 and a 1-year high of $6.70. The company has a market capitalization of $661.16 million, a price-to-earnings ratio of -3.34 and a beta of 1.45. The business has a 50 day moving average price of $4.96 and a two-hundred day moving average price of $4.29.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company grew its holdings in Adaptive Biotechnologies by 5.9% during the second quarter. The Manufacturers Life Insurance Company now owns 48,834 shares of the company’s stock valued at $177,000 after purchasing an additional 2,710 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in shares of Adaptive Biotechnologies by 30.8% in the third quarter. Vontobel Holding Ltd. now owns 17,000 shares of the company’s stock worth $87,000 after buying an additional 4,000 shares during the last quarter. JTC Employer Solutions Trustee Ltd bought a new stake in shares of Adaptive Biotechnologies during the 3rd quarter worth $26,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in Adaptive Biotechnologies by 29.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,576 shares of the company’s stock valued at $131,000 after buying an additional 5,826 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in Adaptive Biotechnologies in the 3rd quarter worth $34,000. 99.17% of the stock is owned by institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.